|By Marketwired .||
|July 14, 2014 07:02 AM EDT||
BEVERLY, MA -- (Marketwired) -- 07/14/14 -- Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin, Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.
"I am very proud of our team and all that we have accomplished with Brilacidin in such a short period of time. We were confident from the minute we acquired the rights that our biological understanding of the compound would lead to different formulations to treat a broad spectrum of indications that are in dire need of efficacious therapies," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "The initial thrust of our efforts with this new formulation is centered on infected diabetic foot ulcers, a substantial market opportunity possibly in the billions of dollars. Given the global diabetes epidemic and fact that foot ulceration precedes 85 percent of diabetes-related amputations, many disciplines are researching new treatments, but with limited success. We are optimistic that the novelty and robust activity demonstrated by Brilacidin in infective wound healing could be the breakthrough drug that the world is looking for."
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT:
Discussions of cloud computing have evolved in recent years from a focus on specific types of cloud, to a world of hybrid cloud, and to a world dominated by the APIs that make today's multi-cloud environments and hybrid clouds possible. In this Power Panel at 17th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the importance of customers being able to use the specific technologies they need, through environments and ecosystems that expose their APIs to make true ...
Nov. 27, 2015 02:00 AM EST Reads: 502
In today's enterprise, digital transformation represents organizational change even more so than technology change, as customer preferences and behavior drive end-to-end transformation across lines of business as well as IT. To capitalize on the ubiquitous disruption driving this transformation, companies must be able to innovate at an increasingly rapid pace. Traditional approaches for driving innovation are now woefully inadequate for keeping up with the breadth of disruption and change facin...
Nov. 27, 2015 01:30 AM EST Reads: 454
Nov. 27, 2015 01:00 AM EST Reads: 457
Nov. 27, 2015 01:00 AM EST Reads: 303
Nov. 27, 2015 01:00 AM EST Reads: 418
Nov. 27, 2015 01:00 AM EST Reads: 551
Nov. 27, 2015 12:45 AM EST Reads: 392
Nov. 27, 2015 12:00 AM EST Reads: 332
Nov. 26, 2015 10:00 PM EST Reads: 392
Nov. 26, 2015 04:00 PM EST Reads: 382
Nov. 26, 2015 03:30 PM EST Reads: 526
Nov. 26, 2015 03:15 PM EST Reads: 521
Nov. 26, 2015 02:15 PM EST Reads: 499
Nov. 26, 2015 01:00 PM EST Reads: 392
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Nov. 26, 2015 01:00 PM EST Reads: 291